PLEASE JOIN US
GIST EDUCATIONAL CONFERENCE AND LUNCHEON
Date: Tuesday, April 21, 2015
Time: 9:30 a.m. to 1:30 p.m., with an optional lab tour to follow
Location: OHSU Center for Health & Healing
3303 SW Bond Ave, Portland, OR 97239
The OHSU Knight Cancer Institute and the GIST Cancer Research Fund
cordially invite you to Oregon Health & Science University on
Tuesday, April 21, for a one-day GIST Educational Conference highlighting
advancements in Gastrointestinal Stromal Tumors (GIST) research.
Brian Druker, M.D.
Christopher Corless, M.D., Ph.D.
Michael Heinrich, M.D.
Caroline Macuiba, LCSW, OSW-C
For questions and to RSVP: 503 552-0681 or email@example.com.
We will mail a detailed agenda and parking information.
PfizerRXPathways2014 highlights their efforts to simplify and streamline patient assistant offerings.
Pfizer stresses that they remain committed to helping patients in need get access to our medicines, and sincerely hope that the consolidation of patient assistance offerings will make it even easier for eligible patients to apply and enroll.
- MAY 7TH—MEMORIAL SLOAN KETTERING CANCER CENTER—New York City, NY
- The GIST presentation will be moved from Room 116 to the MSK Board Room, Room 104, within the Rockefeller Research Laboratories building (East 67th Street between York and 1st Aves) because of Hospital Administration meetings.
- MAY 13TH & 14TH—OREGON HEALTH & SCIENCE UNIVERSITY—Portland, OR
- May 13th, OHSU Dinner, 7 pm for patients and care givers at the Vintage Plaza Hotel (Portland). Contact Gail Mansfield (503-620-4893) or Tania (845-634-1174) to RSVP.
The annual GIST Luncheon at Fox Chase Center will be held in the Young Pavilion on the Mezzanine Level of the Fox Chase Cancer Center. The event will begin at noon on Tuesday, April 8th.
When you arrive on campus, please park in the East Garage (or new garage – there will be signs that say GIST Luncheon parking to direct you) and proceed to the entrance on Level A. Upon entering the building, the security guard will direct you to the event (if you don’t see or hear us first).
Should you have any questions or concerns, please feel free to contact Jamie Roche at 215-316-9373 or e-mail Jamie.Roche@fccc.edu . The event will be held at the Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111
The annual GIST and Sarcoma Cancer Research Conference, organized by the GIST Cancer Research Fund, serves as an invaluable forum for patients and their families to hear about the latest advances in the field from scientists and clinicians at Brigham and Women’s Hospital (BWH) and Dana-Farber Cancer Institute (DFCI).
Last year’s event, which was held in April, was no exception. More than a dozen investigators, physicians, and caregivers at the leading edge of research and care from both BWH and DFCI gathered at the conference to share the latest findings, clinical trial updates, and therapeutic advances with patients, which provide them with the knowledge they need to make informed decisions about their own treatment strategies. Below is a brief synopsis of just a few of the many research highlights from the day’s presentations.
Memorial Sloan-Kettering Cancer Center (MSKCC) is preparing for what it calls “a breakthrough clinical trial” that will test a new drug that uses a MEK inhibitor to target ETV1 in combination with imatinib on a small group of newly diagnosed GIST patients with advanced disease.
We hope to begin recruitment in August, said Dr. William Tap, Section Chief of Sarcoma Oncology at MSKCC. The Phase II trial will be small, with only about 45 participants, and will only have
one site at MSKCC in New York City, he said. That’s because “we just want to show that this approach works,” before recruiting for a larger scale trial, Dr. Tap said. There will be a Phase I portion of the trial to define the Phase II doses of the combination regimen.
The trial is unique because most new GIST clinical trials recruit patients that already have taken imatinib, sunitinib or other drugs and have already developed resistance to those drugs. This trial will try to show that treatment with a combination of imatinib and the MEK inhibitor from the start will be even more effective in combating GIST and will reduce the likelihood of secondary mutations that cause resistance.
Novartis Pharmaceuticals is co-developing the MEK inhibitor, MEK162, with Array Biopharma. MEK162 has been through Phase I trials and recently completed a Phase II trial in NRAS-mutant melanoma.
Dr. Tap said the research that opened the way to this new approach was led by his colleague at MSKCC, Dr. Ping Chi. She was able to show that ETV1, a transcription factor, was essential to the survival of GIST; while it was hard to target ETV1 because it didn’t have molecule-binding pockets that could be blocked by drugs, she found a way around this problem by discovering that MEK inhibitors could do that job.
“MEK inhibitors alone doesn’t seem to be great, but by doing combination therapy with imatinib we get a dramatic response,” Dr. Chi said. ETV1 is a master regulator that is highly expressed in all GISTS.
“Ping’s discovery is one of the major discoveries that we have seen in GIST research since the discovery of KIT,” Dr. Tap said.
ETV1 inhibitor takes lead in combination approach to clinical trials
Posted by Phil Avila – May 20, 2013 – News, Research
In 2010, Dr. Chi published a study she led, “ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours,” in Nature.